Solid phase synthesis of anthraquinone peptides and their evaluation as topoisomerase I inhibitors

Journal of Peptide Science

Volumn 11, Issue 7, 2005, Pages 417-423

  Giles, Gregory I ^a   Sharma, Ram P ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Anthraquinone peptide derivatives; Topoisomerase I inhibitors

Indexed keywords

4 HYDROXYANTHRAQUINONE 1 YL BETA ALANYLGLYCYLAMIDE; 4 HYDROXYANTHRAQUINONE 1 YLALANYLGLYCYLAMIDE; 4 HYDROXYANTHRAQUINONE 1 YLASPARAGINYLTHREONYLGLUTAMINYLALANYLGLYCYLAMIDE; 4 HYDROXYANTHRAQUINONE 1 YLGLYCYL BETA ALANYLHYDROXIDE; 4 HYDROXYANTHRAQUINONE 1 YLGLYCYLGLYCYLHYDROXIDE; 4 HYDROXYANTHRAQUINONE 1 YLGLYCYLGLYCYLLYSYLARGINYLALANYLARGINYLGLUTAMINE; 4 HYDROXYANTHRAQUINONE 1 YLGLYCYLSERYLALANYLGLYCYLAMIDE; 4 HYDROXYANTHRAQUINONE 1 YLNITROPHENYLALANINE; 4 HYDROXYANTHRAQUINONE 1 YLPHENYLHYDROXIDE; 4 HYDROXYANTHRAQUINONE 1 YLSERYLGLYCYLAMIDE; 4 HYDROXYANTHRAQUINONE 1 YLTYROSYL BETA ALANYLHYDROXIDE; 4 HYDROXYANTHRAQUINONE 1 YLTYROSYLALANYLHYDROXIDE; 4 HYDROXYANTHRAQUINONE 1 YLTYROSYLGLYCYLAMIDE; 4 HYDROXYANTHRAQUINONE 1 YLTYROSYLGLYCYLHYDROXIDE; ANTHRACENE DERIVATIVE; ANTHRAQUINONE DERIVATIVE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE INHIBITOR; LEUCOQUINIZARIN; QUINIZARIN; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; CANCER CHEMOTHERAPY; COMBINATORIAL LIBRARY; CONTROLLED STUDY; DNA DETERMINATION; DRUG DETERMINATION; DRUG SYNTHESIS; DRUG TARGETING; ENZYME INHIBITION; MALIGNANT NEOPLASTIC DISEASE; METHODOLOGY; PRIORITY JOURNAL; PROTEIN PURIFICATION; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SOLID PHASE SYNTHESIS;

ANTHRACENES; ANTHRAQUINONES; CAMPTOTHECIN; DNA TOPOISOMERASES, TYPE I; DRUG EVALUATION, PRECLINICAL; PEPTIDES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 21844473492     PISSN: 10752617     EISSN: None     Source Type: Journal    
DOI: 10.1002/psc.635     Document Type: Article

References (20)

1. Hsiang Y-H, Hertzberg R, Hecht S, Liu L. Camptothecin induces protein-linked breaks via mammalian topoisomerase I. J. Biol. Chem. 1985; 260: 14 873-14 878.
2. Myers CE, Mimnaugh EG, Sinha BK. Chapter XIV. Biochemical mechanisms of tumour cell kill by the anthracyclines. In Anthracycline and Anthracenedione Based Anticancer Agents, Lown J. (ed.). Elsevier Science: Amsterdam, 1988: 528-556.
3. Hsiang Y-H, Liu L. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res. 1988; 48: 1722-1726.
4. Garnier-Suillerut A. Chapter IV. Metal anthracycline and anthracenedione based complexes as a new class of anticancer agent. In Anthracycline and Anthracenedione Based Anticancer Agents, Lown J (ed.). Elsevier Science: Amsterdam, 1988; 130-157.
5. Muller I, Jenner A, Bruchelt G, Niethamer D, Halliwell B. Effect of concentration on the cytotoxic mechanism of doxorubicin apoptosis and oxidative DNA damage. Biochem. Biophys. Res. Commun. 1997; 230: 254-257.
6. Murdock K, Child R, Fabio P, Angier R, Wallace R, Durr F, Citarella R. Antitumour agents 1. 1,4-bis[(aminoalkyl)aminol-9, 10-anthracenediones. J. Med. Chem. 1979; 22: 1024-1030.
7. Zee-Cheng R, Podrebarac E, Menon C, Cheng C. Structural modification study of bis(substituted aminoalkylamino)anthraquinones. An evaluation of the relationship of the [2-[(2-hydroxyethyl)amino]-ethyl]amino side chain with antineoplastic activity. J. Med. Chem. 1979; 22: 501-505.
8. Kalopissis G, Bugaut A. Basic anthraquinone hair dye. Chem. Abstr. 1970; 73: 59.
9. Zagotto G, Mitaritonna G, Sissi C, Palumbo M. New peptidyl-anthraquinones: synthesis and DNA binding. J. Med. Chem 1996; 39: 3114-3122.
10. Morier-Teissier E, Boitte N, Helbecque N, Jean-Luc B, Pommery N, Duvalet J, Fournier C, Hecquet B, Catteau J, Henichart J. Synthesis and antitumour properties of an anthraquinone bisubstituted by the copper chelating peptide Gly-Gly-L-His. J. Med. Chem. 1993; 36: 2084-2090.
11. Cummings J, Macpherson J, Meikle I, Smyth J. Development of anthracenyl-amino acid conjugates as topoisomerase I and II inhibitors that circumvent drug resistance. Biochem-Pharm. 1996; 52: 979-990.
12. Meikle I, Cummings J, Macpherson J, Smyth J. Identification of anthracenyl-dipeptide conjugates as novel topoisomerase I and II inhibitors and their evaluation as potential anticancer drugs. Anti-Cancer Drug Design 1995; 10: 515-527.
13. Meikle I, Cummings J, Macpherson J, Hadfield J, Smyth J. Biochemistry of topoisomerase I and II inhibition by anthracenyl-amino acid conjugates. Biochem. Pharm 1995; 49: 1747-1757.
14. Greenhalgh C, Hughes N. The reaction of leucoquinizarins with alkylenediamines. J. Chem. Soc (C) 1968; 1284-1288.
15. Bates A, Maxwell A. DNA Topology, Rickwood D (ed.). Oxford University Press: Oxford, 1993.
16. Hertzberg R, Caranfa M, Hecht S. On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex. Biochemistry 1989; 28: 4629-4638.
17. Redinbo M, Stewart L, Kuhn P, Champoux J, Hol W. Crystal structure of human topoisomerase I in covalent and noncovalent complexes with DNA. Science 1998; 279: 1504-1513.
18. Fassberg J, Stella VJ. A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J. Pharm. Sci. 1992; 81: 676-684.
19. Denizli A, Piskin E. Dye-ligand affinity systems. J. Biochem. Biophys. Methods 2001; 49: 391-416.
20. Gaylord BS, Heeger AJ, Bazan GC. DNA detection using water-soluble conjugated polymers and peptide nucleic acid probes. Proc. Natl Acad. Sci. USA 2002; 99: 10 954-10 957. Epub 2002 Aug 07.